Avatar

An Exhaled Breath Biopsy Earmarks Exclusive Screening for Malignant Pleural Mesothelioma

By Kevin Lamote
21 views
February 1, 2019
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
15:02
Michelle Shiller

Value of NGS in Solid Tumors

13:53
AACR 2023 Conference Coverage

First-in-Class, First-in-Human Phase 1 Trial of VT3989, an Inhibitor…

Feat. T. Yap
36:31
Oluf Dimitri Røe

Emerging Biomarkers for Mesothelioma: Prognostic/Predictive Biomarke…

20:33
Fereidoun Abtin

Discussion on Malignant Pleural Mesothelioma: Outcomes and Effects o…

18:10
Raja Flores

The Role of Decortication in Mesothelioma

18:47
Total Health

Updates in the Management of NSCLC: Systemic Therapy Year in Review

Feat. W. Iams
57:44
Vogl, NY

Vogl,NY on How to Ask Good Questions at Medical Meetings

Feat. S. Vogl
35:40
Balazs Halmos

Year in Review: Lung Cancer

11:07
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "ADAURA Trial Key Learnings & Clinical…

Feat. J. West
17:20
Total Health

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Feat. J. Porter
08:49
David Carbone

The Use of IO Doublet in PD-L1-Negative NSCLC

26:38
University of Colorado Department of Medicine

Key to Successful Lung Cancer Screening and Lung Nodule Program

Feat. N. Thomas
27:04
Fengting Yan

Cancer Screening Molecular Tools

25:35
Total Health

NGS and Liquid Biopsy: Overcoming Challenges in Widespread Testing

Feat. S. Kazmi
13:19
IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage

Duration of Immunotherapy Beyond 2 Years for Patients With Advanced …

Feat. E. Rodriguez
25:18
Janakiraman Subramanian

Updates in Small Cell Lung Carcinoma

07:05
UNC Lineberger Comprehensive Cancer Center

Lung Cancer Screening in Primary Care

Feat. N. Robertson
18:35
2023 Evolution Conference

Recent Updates in SCLC

Feat. S. Kazmi
07:43
Yale Cancer Center

2024 Updates on NSCLC Targeted Therapies: FLAURA2 Trial - Osimertini…

Feat. P. Janne
30:27
Insights from 2023 ESMO Annual Meeting

Perioperative Immunotherapy Strategies in Resectable NSCLC After ESM…

Feat. G. Mountzios